Form 4: Intuitive Surgical SVP Mark Brosius Executes Stock Sales Under 10b5-1 Trading Plan

Mark Brosius, SVP & Chief Manufacturing and Supply Chain Officer at Intuitive Surgical, sold shares of ISRG common stock on May 15 and 16, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Mark Brosius, a Senior Vice President at Intuitive Surgical, sold shares of the company's common stock on May 15 and May 16, 2025.
• The sales were executed under a pre-arranged trading plan that complies with SEC Rule 10b5-1.
• On May 15, 2025, 22 shares were sold at a price of $560 per share.
• On May 16, 2025, 20 shares were sold at a price of $563.81 per share.
• Following these transactions, Brosius directly owns 1,983 shares of Intuitive Surgical common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock sales by an executive, which is neither particularly positive nor negative. The sales are conducted under a pre-arranged plan, reducing the potential for negative interpretation.

Industry Context

Executive stock sales are a common occurrence, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-planned. Investors often monitor these filings for insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Executive compensation and stock sales are common across the medical device industry, with companies like Medtronic, Stryker, and Johnson & Johnson also seeing regular insider transactions.
• The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.

Stakeholder Impact

• The stock sales could have a minor impact on shareholder sentiment, but the pre-planned nature of the transactions mitigates this impact.

Key Dates

Keywords

Form 4, Intuitive Surgical, ISRG, Mark Brosius, Stock Sale, 10b5-1 Trading Plan, SEC, Insider Trading